<DOC>
	<DOCNO>NCT00147485</DOCNO>
	<brief_summary>AG-024322 may work cancer stop cancer cell multiply . AG-024322 intravenous drug new class drug call cyclin-dependent kinase ( CDK inhibitor ) . This research study first time AG-024322 give people .</brief_summary>
	<brief_title>A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer</brief_title>
	<detailed_description>The study prematurely discontinue due inability compound adequately differentiate treatment option clinical endpoint necessary product profile April 13 , 2007 . Safety profile reason lead discontinuation program .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Advanced solid tumor follicular diffuse large cell nonHodgkin 's lymphoma , histologically cytologically proven diagnosis refractory intolerant establish therapy know provide clinical benefit condition Adequate blood cell count , kidney function liver function ECOG score 0 1 . Prior highdose chemotherapy require hemapoietic stem cell rescue Previous radiation therapy &gt; 25 % bone marrow Active unstable cardiac disease history heart attack within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>